Home » Stocks » CATB

Catabasis Pharmaceuticals, Inc. (CATB)

Stock Price: $1.63 USD -0.03 (-1.81%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 126.58M
Revenue (ttm) n/a
Net Income (ttm) -199.43M
Shares Out 76.95M
EPS (ttm) -9.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $1.63
Previous Close $1.66
Change ($) -0.03
Change (%) -1.81%
Day's Open 1.66
Day's Range 1.63 - 1.68
Day's Volume 197,588
52-Week Range 1.25 - 8.59

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON--(BUSINESS WIRE)--Catabasis will present information on its lead program QLS-215 at the Ladenburg Thalmann 2021 Healthcare Conference.

3 weeks ago - Business Wire

Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest bio...

Other stocks mentioned: KIN, APRE, IKT
1 month ago - Benzinga

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

2 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update

2 months ago - Business Wire

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

Other stocks mentioned: AGRX, AQMS, CKPT, HEPA, IFRX, LLNW
3 months ago - InvestorPlace

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

4 months ago - Business Wire

With the trading day halfway over, the broad markets were making yet another strong push.

Other stocks mentioned: ORCL, TSLA, AEP, BHVN, ESPR, KDP, QSR ...
4 months ago - 24/7 Wall Street

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences.

4 months ago - Business Wire

Catabasis Pharma (CATB) stock is soaring higher on Friday after announcing its acquisition of Quellis Biosciences and a PIPE. The post CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today appear...

6 months ago - InvestorPlace

Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Catabasis Pharmaceuticals (CATB) stock is taking off on Wednesday despite a lack of news from the biopharmaceutical company. The post Catabasis Pharmaceuticals: 9 Things for Potential CATB Stock Investo...

7 months ago - InvestorPlace

There are some investors who buy stocks that are trading below their liquidation value because they believe they can make remarkable gains out of their investments after the market has reassessed the sh...

Other stocks mentioned: KBSF, NVFY
7 months ago - GuruFocus

Catabasis Pharmaceuticals (CATB) news for Tuesday includes incredibly poor results from a clinical trial hammering CATB stock hard. The post Catabasis Pharmaceuticals News: Why CATB Stock Is Plummeting ...

9 months ago - InvestorPlace

Catabasis is approaching its highly anticipated Q4 readout for their Phase III PolarisDMD study. If the data is acceptable, Catabasis expects to file an NDA in 2021.

9 months ago - Seeking Alpha

Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

Catabasis Pharmaceuticals (CATB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

Catabasis: Worth A Look Ahead Of Phase III Data

1 year ago - Seeking Alpha

Catabasis Pharmaceuticals Inc. (CATB) CEO Jill Milne on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.

1 year ago - Zacks Investment Research

Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) has announced that it completed the enrollment for its late-stage Duchenne muscular dystrophy (DMD) study.

1 year ago - 24/7 Wall Street

Catabasis Pharmaceuticals (CATB) CEO, Jill Milne on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Catabasis enrollment is moving fast, having completed enrollment in certain countries, and is on track to report results from the phase 3 PolarisDMD study by second half of 2020.

2 years ago - Seeking Alpha

Catabasis Pharmaceuticals, Inc. (CATB) CEO Jill Milne on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Catabasis (CATB) beats earnings estimates in the fourth quarter of 2018. The company has no revenues. Shares up.

2 years ago - Zacks Investment Research

About CATB

Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.

Industry
Biotechnology
IPO Date
Jun 25, 2015
Stock Exchange
NASDAQ
Ticker Symbol
CATB
Full Company Profile

Financial Performance

Financial Statements